Esther Rajavelu files SEC Form 4 disclosures for Spero Therapeutics, Inc.. They have made 6 open-market trades across 1 company since 2024, most recently 2026-05-04.
CIK 0001903716
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRO | 986,851 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-05-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | SELL | 2026-05-04 | 2026-05-06 | $2.51 | $63K | -0.6% | +9.3% | -52.1% |
| SPRO | SELL | 2026-02-06 | 2026-02-09 | $2.36 | $207K | -4.2% | +7.9% | +6.7% |
| SPRO | SELL | 2026-02-02 | 2026-02-04 | $2.20 | $41K | +4.4% | +2.2% | +7.3% |
| SPRO | SELL | 2025-11-07 | 2025-11-12 | $2.37 | $191K | -10.5% | -12.8% | -11.3% |
| SPRO | SELL | 2025-02-05 | 2025-02-05 | $0.78 | $16K | -8.2% | -12.9% | -34.0% |
| SPRO | SELL | 2024-11-07 | 2024-11-12 | $1.31 | $53K | -10.8% | -15.4% | -38.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.